NATUS MEDICAL INC (NTUS) Fundamental Analysis & Valuation

NASDAQ:NTUS • US6390501038

Current stock price

32.96 USD
+0.03 (+0.09%)
At close:
32.96 USD
0 (0%)
After Hours:

This NTUS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NTUS Profitability Analysis

1.1 Basic Checks

  • In the past year NTUS was profitable.
NTUS Yearly Net Income VS EBIT VS OCF VS FCFNTUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M 60M

1.2 Ratios

Industry RankSector Rank
ROA 2.23%
ROE 2.94%
ROIC 5.05%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NTUS Yearly ROA, ROE, ROICNTUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 5 -5 10

1.3 Margins

Industry RankSector Rank
OM 7.06%
PM (TTM) 2.65%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NTUS Yearly Profit, Operating, Gross MarginsNTUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. NTUS Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), NTUS is destroying value.
  • The number of shares outstanding for NTUS has been increased compared to 1 year ago.
  • NTUS has a better debt/assets ratio than last year.
NTUS Yearly Shares OutstandingNTUS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M
NTUS Yearly Total Debt VS Total AssetsNTUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 6.54 indicates that NTUS is not in any danger for bankruptcy at the moment.
  • NTUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.54
ROIC/WACC0.56
WACC8.98%
NTUS Yearly LT Debt VS Equity VS FCFNTUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M

2.3 Liquidity

  • NTUS has a Current Ratio of 2.54. This indicates that NTUS is financially healthy and has no problem in meeting its short term obligations.
  • A Quick Ratio of 1.90 indicates that NTUS should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 1.9
NTUS Yearly Current Assets VS Current LiabilitesNTUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. NTUS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 147.06% over the past year.
  • NTUS shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -5.94% yearly.
  • NTUS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.56%.
  • The Revenue has been growing slightly by 4.39% on average over the past years.
EPS 1Y (TTM)147.06%
EPS 3Y-5.46%
EPS 5Y-5.94%
EPS Q2Q%37.5%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y-3.75%
Revenue growth 5Y4.39%
Sales Q2Q%4.26%

3.2 Future

  • Based on estimates for the next years, NTUS will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.74% on average per year.
  • Based on estimates for the next years, NTUS will show a small growth in Revenue. The Revenue will grow by 4.27% on average per year.
EPS Next Y22.4%
EPS Next 2Y15.52%
EPS Next 3Y15.29%
EPS Next 5Y15.74%
Revenue Next Year5.1%
Revenue Next 2Y4.79%
Revenue Next 3Y4.1%
Revenue Next 5Y4.27%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
NTUS Yearly Revenue VS EstimatesNTUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
NTUS Yearly EPS VS EstimatesNTUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

1

4. NTUS Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 26.16, NTUS can be considered very expensive at the moment.
  • When comparing the Price/Earnings ratio of NTUS to the average of the S&P500 Index (25.96), we can say NTUS is valued inline with the index average.
  • A Price/Forward Earnings ratio of 20.58 indicates a rather expensive valuation of NTUS.
  • The average S&P500 Price/Forward Earnings ratio is at 24.04. NTUS is around the same levels.
Industry RankSector Rank
PE 26.16
Fwd PE 20.58
NTUS Price Earnings VS Forward Price EarningsNTUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 17.23
NTUS Per share dataNTUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • NTUS's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • NTUS's earnings are expected to grow with 15.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.17
PEG (5Y)N/A
EPS Next 2Y15.52%
EPS Next 3Y15.29%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NTUS Dividend Analysis

5.1 Amount

  • No dividends for NTUS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NTUS Fundamentals: All Metrics, Ratios and Statistics

NATUS MEDICAL INC

NASDAQ:NTUS (7/20/2022, 8:05:33 PM)

After market: 32.96 0 (0%)

32.96

+0.03 (+0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-05
Earnings (Next)08-04
Inst Owners91.2%
Inst Owner ChangeN/A
Ins Owners0.64%
Ins Owner Change0%
Market Cap1.14B
Revenue(TTM)478.31M
Net Income(TTM)12.67M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 26.16
Fwd PE 20.58
P/S 2.38
P/FCF N/A
P/OCF N/A
P/B 2.65
P/tB N/A
EV/EBITDA 17.23
EPS(TTM)1.26
EY3.82%
EPS(NY)1.6
Fwd EY4.86%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS13.83
BVpS12.46
TBVpSN/A
PEG (NY)1.17
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 2.23%
ROE 2.94%
ROCE N/A
ROIC 5.05%
ROICexc N/A
ROICexgc 9.3%
OM 7.06%
PM (TTM) 2.65%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 1.9
Altman-Z 6.54
F-Score8
WACC8.98%
ROIC/WACC0.56
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)147.06%
EPS 3Y-5.46%
EPS 5Y-5.94%
EPS Q2Q%37.5%
EPS Next Y22.4%
EPS Next 2Y15.52%
EPS Next 3Y15.29%
EPS Next 5Y15.74%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y-3.75%
Revenue growth 5Y4.39%
Sales Q2Q%4.26%
Revenue Next Year5.1%
Revenue Next 2Y4.79%
Revenue Next 3Y4.1%
Revenue Next 5Y4.27%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

NATUS MEDICAL INC / NTUS Fundamental Analysis FAQ

What is the fundamental rating for NTUS stock?

ChartMill assigns a fundamental rating of 5 / 10 to NTUS.


What is the valuation status of NATUS MEDICAL INC (NTUS) stock?

ChartMill assigns a valuation rating of 3 / 10 to NATUS MEDICAL INC (NTUS). This can be considered as Overvalued.


How profitable is NATUS MEDICAL INC (NTUS) stock?

NATUS MEDICAL INC (NTUS) has a profitability rating of 6 / 10.


How financially healthy is NATUS MEDICAL INC?

The financial health rating of NATUS MEDICAL INC (NTUS) is 7 / 10.


What is the earnings growth outlook for NATUS MEDICAL INC?

The Earnings per Share (EPS) of NATUS MEDICAL INC (NTUS) is expected to grow by 22.4% in the next year.